Despite a restricted FDA label, Sarepta Therapeutics has seen early commercial success with its Duchenne muscular dystrophy (DMD) gene therapy Elevidys. This year, the company aims to dramatically ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback